SEM Observation of the Filter after Administration of Blinatumomab: A Possibility of Leakage during Home Administration Using a Portable Infusion Pump

SEM Observation of the Filter after Administration of Blinatumomab: A Possibility of Leakage during Home Administration Using a Portable Infusion Pump

Blinatumomab (Blincyto<sup>®</sup> injection solution) is classified as a bispecific T-cell engaging (BiTE) antibody and is intended for the treatment of relapsed/refractory acute lymphoblastic leukemia. It requires continuous infusion to maintain therapeutic levels. Therefore, it is oft...

Full description

Bibliographic Details
Main Authors:	Megumi Takano, Motoki Inoue, Yuko Ikeda, Hidenori Kage, Tohru Inokawa, Kazuhiko Nakadate, Takeo Yasu, Yasumasa Tsuda, Kazumi Goto
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	blinatumomab leakage continuous infusion bispecific T-cell engagers polysorbate 80 filter
Online Access:	https://www.mdpi.com/1422-0067/24/6/5729

Similar Items

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
by: Hagop M. Kantarjian, et al.
Published: (2021-11-01)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
by: Shang-Ju Wu, et al.
Published: (2023-05-01)

The effect of polysorbate 20 and polysorbate 80 on the solubility of quercetin
by: Tristiana Erawati, et al.
Published: (2023-03-01)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
by: Virginie Nägele, et al.
Published: (2017-05-01)

The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
by: Rita Tavarozzi, et al.
Published: (2022-02-01)

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation
by: Ottoboni T, et al.
Published: (2018-03-01)

Combination of Donor Lymphocyte Infusion and Blinatumomab for B-Cell Lymphoblastic Lymphoma Relapse after Allogeneic Stem-Cell Transplantation
by: Jinichi Mori, et al.
Published: (2023-08-01)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
by: Franquiz MJ, et al.
Published: (2020-02-01)

Scientific Opinion on the re‐evaluation of polyoxyethylene sorbitan monolaurate (E 432), polyoxyethylene sorbitan monooleate (E 433), polyoxyethylene sorbitan monopalmitate (E 434), polyoxyethylene sorbitan monostearate (E 435) and polyoxyethylene sorbitan tristearate (E 436) as food additives
by: EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS)
Published: (2015-07-01)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01)

Polysorbate 80 – Modulated nanocrystallization for enhancement of griseofulvin solubility
by: Emmanuel O. Olorunsola, et al.
Published: (2024-01-01)

A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
by: Yasuto Yamamoto, et al.
Published: (2022-05-01)

Effects of Tween 80 on growth and biofilm formation in laboratory media
by: Christina Krogsård Nielsen, et al.
Published: (2016-11-01)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020-06-01)

Efficient Combination Chemo-Sonodynamic Cancer Therapy Using Mitochondria-Targeting Sonosensitizer-Loaded Polysorbate-Based Micelles
by: Hyeon Ju Kang, et al.
Published: (2024-03-01)

Nanoparticles Enhanced Ligninolytic Enzymes Activity of Rotten Wood Fungus Phanerochaete chrysosporium
by: Aisha M. H. Al-Rajhi, et al.
Published: (2024-02-01)

Adaptation of the Kirkstall QV600 LLI Microfluidics System for the Study of Gastrointestinal Absorption by Mass Spectrometry Imaging and LC-MS/MS
by: Chloe E. Spencer, et al.
Published: (2022-02-01)

From micelle to microemulsion: an investigation of structural changes using molecular dynamics
by: Amir Amani, et al.
Published: (2015-03-01)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
by: Zhaoming Wang, et al.
Published: (2021-12-01)

Deproteinization of Chitin Extracted with the Help of Ionic Liquids
by: Douglas R. Lyon, et al.
Published: (2022-06-01)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
by: Hoda Pourhassan, et al.
Published: (2023-08-01)

Cytofluorimetric assay to investigate variability in blinatumomab in vitro response
by: Stefania Braidotti, et al.
Published: (2022-01-01)

Case report: Donor lymphocyte infusion and blinatumomab as treatment for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
by: Flavia Antonucci, et al.
Published: (2024-03-01)

Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia
by: Yamini K. Kathari, et al.
Published: (2024-03-01)

A Unique Enhancement of <i>Propionibacterium freudenreichii</i>’s Ability to Remove Pb(II) from Aqueous Solution by Tween 80 Treatment
by: Fanny George, et al.
Published: (2022-08-01)

Nanosuspension enhances dissolution rate and oral bioavailability of Terminalia arjuna bark extract in vivo and in vitro
by: Fatiqa Zafar, et al.
Published: (2020-01-01)

Polysorbate 80 and <it>Helicobacter pylori</it>: a microbiological and ultrastructural study
by: Figura Natale, et al.
Published: (2012-09-01)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma
by: Masuho Saburi, et al.
Published: (2024-01-01)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
by: Alexandra Semchenkova, et al.
Published: (2022-04-01)

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
by: Massimiliano Bonifacio, et al.
Published: (2022-01-01)

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
by: Nicola Stefano Fracchiolla, et al.
Published: (2023-09-01)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
by: Francesco Paolo Tambaro, et al.
Published: (2020-09-01)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
by: Songmi Wang, et al.
Published: (2023-01-01)

Brain-Targeted Polysorbate 80-Emulsified Donepezil Drug-Loaded Nanoparticles for Neuroprotection
by: Xiaojun Tao, et al.
Published: (2021-08-01)

Neurospecific fabrication and toxicity assessment of a PNIPAM nanogel encapsulated with trans-tephrostachin for blood-brain-barrier permeability in zebrafish model
by: Pitchai Arjun, et al.
Published: (2022-08-01)

Preparation and physical properties of itraconazole-loaded nanoemulsions using pineapple starch as co-emulsifier
by: Su Su Latt, et al.
Published: (2016-02-01)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
by: Katarzyna Pawinska-Wasikowska, et al.
Published: (2022-01-01)

Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
by: Richard Burt, et al.
Published: (2019-03-01)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
by: Hagop Kantarjian, et al.
Published: (2023-05-01)